In Orphan Europe we believe that the approach to the development of orphan drugs must be based on combined efforts between the industry, patients and the medical community with the overall aim to improve the lives of affected individuals and access to therapies. Orphan Europe works closely with industry, academia and patient organisations, as well as European and member state authorities.